PROVENTIL Drug Patent Profile

Which patents cover Proventil, and what generic alternatives are available?

Proventil is a drug marketed by Schering and Kindeva and is included in six NDAs.

The generic ingredient in PROVENTIL is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Proventil

A generic version of PROVENTIL was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5^th, 1989.

Summary for PROVENTIL

US Patents:	0
Applicants:	2
NDAs:	6
Raw Ingredient (Bulk) Api Vendors:	133
Clinical Trials:	19
Drug Prices:	Drug price information for PROVENTIL
Drug Sales Revenues:	Drug sales revenues for PROVENTIL
DailyMed Link:	PROVENTIL at DailyMed

See drug prices for PROVENTIL

See drug sales revenues for PROVENTIL

Recent Clinical Trials for PROVENTIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AstraZeneca	Phase 2
University Medical Center of Southern Nevada	N/A
Asthma Management Systems	Phase 4

See all PROVENTIL clinical trials

US Patents and Regulatory Information for PROVENTIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	PROVENTIL	albuterol	AEROSOL, METERED;INHALATION	017559-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	PROVENTIL	albuterol sulfate	TABLET;ORAL	017853-002	May 7, 1982		DISCN	Yes	No
Schering	PROVENTIL	albuterol sulfate	SYRUP;ORAL	018062-001	Jan 19, 1983		DISCN	Yes	No
Kindeva	PROVENTIL-HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	020503-001	Aug 15, 1996	AB1	RX	Yes	Yes

Expired US Patents for PROVENTIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	PROVENTIL	albuterol sulfate	SYRUP;ORAL	018062-001	Jan 19, 1983	4,499,108
Schering	PROVENTIL	albuterol sulfate	TABLET;ORAL	017853-002	May 7, 1982	3,644,353
Schering	PROVENTIL	albuterol sulfate	SOLUTION;INHALATION	019243-002	Jan 14, 1987	3,644,353
Schering	PROVENTIL	albuterol sulfate	SYRUP;ORAL	018062-001	Jan 19, 1983	3,705,233

International Patents for PROVENTIL

See the table below for patents covering PROVENTIL around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	6713016
United Kingdom	1200886
Belgium	704037
Israel	28643	1-PHENYL-2-AMINOETHANOL DERIVATIVES

Market Dynamics and Financial Trajectory for PROVENTIL (Albuterol)

Last updated: January 15, 2026

Executive Summary

PROVENTIL, a trade name for albuterol (also known as salbutamol), is a bronchodilator primarily used for managing asthma, chronic obstructive pulmonary disease (COPD), and other respiratory ailments. Over recent years, the drug has maintained a critical market position driven by increasing respiratory disease prevalence, advancements in inhalation therapies, and expanding global healthcare infrastructure. This article provides an in-depth analysis of the current market environment, upcoming trends, competitive landscape, and financial prospects for PROVENTIL, supported by recent data, policies, and competitive strategies.

---

What Are the Market Drivers for PROVENTIL?

1. Rising Global Prevalence of Respiratory Diseases

• According to the Global Initiative for Asthma (GINA), over 300 million people worldwide suffer from asthma, with COPD affecting over 250 million individuals globally [1].
• Increasing urbanization, pollution, smoking rates, and aging populations contribute to the rising incidence.

2. Expanding Access to Respiratory Care in Emerging Markets

• Developing regions such as Asia-Pacific and Latin America are experiencing increased healthcare infrastructure development and awareness campaigns.
• The WHO reports that accessibility to inhalers and bronchodilators like PROVENTIL is growing, especially in countries with underserved populations.

3. Innovation in Inhalation Delivery Devices

• Advancements in metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) enhance patient adherence and efficacy.
• Companies investing in smarter inhaler technologies (e.g., digital tracking) bolster market growth.

4. Regulatory Environment Favorability and Patent Longevity

• PROVENTIL’s patent expiry in many markets pushes generics development, increasing accessibility but intensifying competition.
• Regulatory adaptations, including approvals for pediatric and combination therapies, open new revenue streams.

---

What Are the Challenges Impacting PROVENTIL’s Market?

1. Competition from Generic and Bioequivalent Products

• The expiration of patent protections in major markets (e.g., U.S. in 2011) led to increased manufacturing of generic albuterol inhalers by competitors like Mylan and Teva.
• Price erosion results in reduced margins for branded versions.

2. Market Saturation and Price Erosion

• The mature market in North America and Europe has seen stabilization or decline in price points, impacting revenue growth.

3. Shift Toward Biologic and Novel Therapies

• For severe asthma, biologics (e.g., omalizumab, mepolizumab) are gaining traction, potentially displacing traditional bronchodilators in certain indications.

4. Regulatory and Reimbursement Policies

• Stringent policies on inhaler environmental impact (e.g., HFA inhalers) may increase manufacturing costs.
• Reimbursement constraints in some countries impact profit margins.

---

How Is the Competitive Landscape Structured?

Key Players	Market Share (% estimates, 2022)	Product Portfolio	Strategic Focus
Teva	35%	Albuterol MDI, DPI	Cost leadership, generics
Mylan	27%	Albuterol inhalers	Price competition, innovation
GlaxoSmithKline	15%	Advair, Ventolin	Brand loyalty, novel formulations
Others	23%	Various	Niche markets, biosimilars

Source: IMS Health, 2022.

Patent and Market Entry Barriers

• Patents on delivery mechanisms and combination therapies limit immediate generic entry.
• Regulatory approvals and manufacturing standards pose barriers for new entrants.

---

Financial Trajectory: Revenue, Pricing, and Market Outlook

Recent Revenue Performance (2020–2022)

Year	Estimated Global Sales (USD billions)	Growth Rate (%)	Major Contributors
2020	$2.4 billion	4%	North America, Europe
2021	$2.6 billion	8%	Emerging markets, new formulations
2022	$2.7 billion	3.85%	Stabilized growth, competition

Factors Influencing Revenue Trends

• Market Saturation: Approaching maturity in many high-income countries.
• Price Competition: Generics cut into revenue margins.
• Emerging Markets: Fast-growing due to rising disease burden and increased access.
• Innovation and New Formulations: Potential to boost revenues via inhaler improvements and fixed-dose combinations.

Price Dynamics and Margins

• Average Wholesale Price (AWP): Approximate $20–$25 per inhaler in the U.S.
• Margins: Branded products maintain 25–30% profit margins, but generic competition reduces profitability.

Projected Market Outlook (2023–2030)

Scenario	Compound Annual Growth Rate (CAGR)	Key Drivers
Optimistic	3–5%	Innovation, expanding emerging markets
Conservative	1–2%	Increased generics, market saturation
Pessimistic	0–1%	Price erosion, competition

Note: Projections based on industry reports, policy evolution, and market dynamics.

---

How Will Policy Changes Shape the PROVENTIL Market?

Policy Area	Impact on PROVENTIL	Notable Developments
Environmental Regulations	Challenges in inhaler manufacturing	Phasing out HFA inhalers under Montreal Protocol
Reimbursement Policies	Cost containment pressures	Shifts toward biosimilars and generics
Patent Laws	Generic market entry	Patent cliffs in key markets (2011, 2019)

Recent Policies and Initiatives

• FDA’s Generic Inhaler Policy (2019): Facilitates approval of generic albuterol inhalers.
• European Union Environmental Targets (2020): Drive innovation toward greener inhaler technologies.

---

How Do Future Trends Impact the Financial Trajectory?

• Digital health integration: Can improve adherence and optimize dosing, potentially increasing product utilization.
• Biosimilars and Specialty Inhalers: Entering the market could commoditize traditional products, reducing margins.
• Personalized medicine: Targeted therapies for severe asthma could divert revenues from classic bronchodilators.

Comparative Analysis: PROVENTIL and Competitors

Parameter	PROVENTIL (Albuterol)	Alternatives
Volume of use	High in acute and chronic segments	Increasing biologics share
Patent status	Expired in many markets	Active patents for new formulations
Pricing	Moderate	Variable; generics driving down costs

---

What Are the Key Takeaways for Stakeholders?

• Market Growth: Driven mainly by emerging markets and technological advancements, though high competition and patent expirations temper growth.
• Revenue Sustainability: Reliant on innovation, strategic pricing, and expanding access.
• Competition: Fierce from generics and biosimilars, necessitating differentiation via formulations or delivery devices.
• Regulatory Dynamics: Policies on environmental impact and reimbursements will shape future market structure.
• Investment Opportunities: Developing greener inhalers, digital adherence solutions, and combination therapies present potential growth avenues.

---

Frequently Asked Questions (FAQs)

1. What role does patent expiry play in PROVENTIL’s market?
Patent expiry in key markets has led to increased generic competition, reducing prices and profit margins but expanding accessibility. Companies are now focusing on innovation and delivery device improvements to maintain market share.

2. How are emerging markets influencing PROVENTIL’s financial prospects?
Growing respiratory disease prevalence, increased healthcare infrastructure, and rising disposable incomes drive demand. These markets represent opportunities for volume-based growth and new product launches.

3. What technological innovations are impacting inhaler therapies?
Smart inhalers, digital adherence tracking, and environmentally friendly propellants are revolutionizing delivery, improving compliance, and aligning with regulatory policies.

4. How is the shift toward biologics affecting traditional bronchodilator sales?
Biologics serve severe asthma cases and are gaining market share, potentially limiting growth for traditional bronchodilators like PROVENTIL in certain segments.

5. What future policies could impact PROVENTIL’s market?
Environmental regulations targeting HFA inhalers and reimbursement reforms favoring biosimilars could alter competitive dynamics and pricing strategies.

---

References

[1] World Health Organization. “Asthma.” 2022.
[2] Global Initiative for Asthma (GINA). “Global Strategy for Asthma Management and Prevention,” 2022.
[3] IMS Health. “Pharmaceutical Market Data,” 2022.
[4] US FDA. “Generic Drug and Biosimilar User Fee Amendments,” 2019.
[5] Montreal Protocol. “Environmental Impact of Inhalers,” 2020.

---

Key Takeaways

• The PROVENTIL market remains vital amid rising respiratory disease trends but faces pressures from patent expirations and competitive generics.
• Innovations in inhaler technology and expansion into emerging markets are critical to sustaining growth.
• Regulatory and environmental policies are pivotal in shaping future market dynamics and product development.
• Strategic focus on device improvements, digital health integration, and sustainable formulations can unlock new revenue streams.
• Stakeholders must balance cost mitigation with innovation to navigate the evolving landscape effectively.

---

This comprehensive analysis aims to inform pharmaceutical executives, investors, and policymakers on PROVENTIL's current market status and future financial prospects.